ASCLETIS-B (01672) rose more than 4% in morning trading. At the time of writing, the stock was up 3.46% to HK$18.82, with a turnover of HK$21.991 million. The company previously announced the initiation of clinical development for ASC30_39FDC and plans to submit an IND application to the U.S. FDA in the third quarter of this year. According to analysis, ASC30 is a self-developed GLP-1 small molecule formulation with both oral and subcutaneous injection options. The oral formulation is set to submit a Phase III clinical plan to the FDA, with the trial expected to officially begin in the third quarter of 2026. Based on current enrollment rates and treatment cycles for weight loss trials, data from this study is anticipated to be available by 2028. It is worth noting that Eli Lilly's Orforglipron received FDA approval on April 1 this year. The commercial pressure on ASC30 and other oral small molecules with similar structures is increasing following Orforglipron's approval. Although ASC30's key advantages lie in oral convenience, dosing frequency, and patient tolerance, from a commercial perspective, both Eli Lilly's sales capabilities and Orforglipron's first-mover market advantage present significant challenges for ASCLETIS-B and ASC30 to overcome in the short term.